Close

Recombinant Human Tumor Necrosis Factor alpha Mutant (CRP0822)

DESCRIPTION CATALOG # SIZE PRICE
Recombinant Human Tumor Necrosis Factor alpha Mutant CRP0822 1mg Please Inquiry

PRODUCT INFORMATION

  • Product Overview
  • The clinical use of the potent anti-tumor activity of TNF-alpha has been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-a mutants with low systemic toxicity has been an intense pharmacological interest. Human TNF-a, which binds to the murine TNF-R55 but not to the mouse TNF-R75, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-a, which binds to both murine TNF receptors. Based on these results, many TNF-a mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro, and exhibited lower systemic toxicity in vivo. Recombinant Human TNF-alpha Variant/Mutant compared with the wild-type, has an amino acid sequence deletion from a.a. 1-7, and the following a.a. substitutes Arg8, Lys9, Arg10 and Phe157 which is proven to have more activity and with less inflammatory side effect in vivo. Recombinant Human TNF-alpha Mutant produced in E. coli is a single, non-glycosylated, polypeptide chain containing 151 amino acids and having a molecular mass of 16,886 Dalton.
  • Specificity
  • The ED50 as determined by the cytolysis of murine L929 cells in the presence of Actinomycin D is less than 0.01 ng/ml, corresponding to a Specific Activity of 1.0 x 108IU/ mg.
  • Endotoxin
  • Less than 0.01ng/ug (0.01IEU/ug) determined by LAL test.
  • Purity
  • >95% as determined by SEC-HPLC and SDS-PAGE .
  • Storage
  • Lyophilized samples are stable for up to twelve months from date of receipt at -20oC to -70oC. Aliquot to avoid repeated freeze-thaw cycles.
  • Reconstitution
  • It is recommended to reconstitute the lyophilized TNF-alpha Mutant in sterile 18MΩ-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.
  • Recombinant Human Tumor Necrosis Factor alpha Mutant
    PDB rendering based on 1TNF.

BACKGROUND

  • Antigen Description
  • TNF is secreted by macrophages, monocytes, neutrophils, T-cells, NK-cells following their stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-alpha while CD8 cells secrete little or no TNF-alpha. The synthesis of TNF-alpha is induced by many different stimuli including interferons, IL2, GM-CSF.
  • Function
  • Cytokine activity, Identical protein binding, Tumor necrosis factor receptor binding
  • Gene ID
  • 7124
  • Synonyms
  • DIF; TNFA; TNFSF2; TNF-alpha;Tumor necrosis factor precursor; TNF-α; Tumor necrosis factor ligand superfamily member 2; Cachectin; TNF alpha human; Tumor necrosis factor human.

Related Products

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.

Online Inquiry

Verification code
Click image to refresh the verification code.

CONTACT US

USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us